<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02455687</url>
  </required_header>
  <id_info>
    <org_study_id>1400046</org_study_id>
    <nct_id>NCT02455687</nct_id>
  </id_info>
  <brief_title>Two Doses of the Intravenous Magnesium Sulfate Versus the Standard Single Dose ,With/ Without the Nebulized Budesonide For the Management of the Severe Asthma Exacerbation in the Emergency Room; A Randomized Controlled Trial.</brief_title>
  <official_title>Two Doses of the Intravenous Magnesium Sulfate Versus the Standard Single Dose With/Without Nebulized Budesonide for the Emergency Management of the Severe Asthma. A Randomized Controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hamad Medical Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hamad Medical Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Many studies have investigated the efficacy and safety of Intravenous magnesium sulfate and
      inhaled steroids in addition to the standard treatment for patients with severe asthma
      attacks.

      In this 2x2 factorial design blinded randomized study, no interaction of hypothesized
      treatments is expected.Investigators hypothesize that two doses of intravenous magnesium
      sulfate,a high dose followed by a (lower) standard dose, will shorten the time to medical
      readiness for discharge compared to a single standard dose followed by placebo.The second
      hypothesis is that nebulized inhaled budesonide will be superior to placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patient with a severe asthma attack will be admitted to the observation area in the Pediatric
      Emergency Center and assessed for eligibility for the study by the attending physician, based
      upon our study inclusion/exclusion criteria.

      Eligible patients will be enrolled after obtaining written consent from the parents. Patients
      will receive routine treatment for a severe asthma attack, such as inhaled bronchodilators,
      plus intravenous steroids and supplementary oxygen if needed. Standard blood work and chest
      X-Ray will be obtained and bronchial asthma severity score will be measured at baseline
      before starting treatment,and then at 4,8,12,24,36,48 hr and thereafter. The medical team as
      well as parents and patient will be blinded to the medications delivered. The patient will be
      randomized into one of the four study groups and adverse effects of the medications in each
      group will be monitored and documented carefully.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 2015</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to medical readiness for discharge.</measure>
    <time_frame>3 years</time_frame>
    <description>Accelerated failure time analyses of each of the blinded interventions will use the entire population,as this is a 2x2 factorial study.We will use retrospective stratification &amp; quantitative interaction analysis to determine if the magnesium or magnesium placebo intervention has a different effect in the budesonide or budesonide placebo group.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall length of the hospital stay (hours/days) .</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of admission to pediatric intensive care unit (%)</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of clinical response in severity score (%)</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of need for revisit to pediatric emergency center for same diagnosis(%)</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Bronchial Asthma</condition>
  <arm_group>
    <arm_group_label>Hi-Mg + Bud</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group one will receive a high,then standard dose of intravenous magnesium sulfate with blinded nebulized budesonide.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hi-Mg + P</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Group two will receive a high,then standard dose of intravenous magnesium sulfate with blinded nebulized normal saline.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Std-Mg + Bud</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group three will receive a single standard dose of intravenous magnesium sulfate plus one dose of intravenous normal saline with blinded nebulized budesonide.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>St-Mg + P</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Group four will receive a single dose of intravenous magnesium sulfate plus one dose of intravenous normal saline with blinded nebulized normal saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hi-dose iv MgSO4</intervention_name>
    <arm_group_label>Hi-Mg + Bud</arm_group_label>
    <arm_group_label>Hi-Mg + P</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nebulized budesonide</intervention_name>
    <arm_group_label>Hi-Mg + Bud</arm_group_label>
    <arm_group_label>Std-Mg + Bud</arm_group_label>
    <other_name>Pulmicort</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Std-dose iv MgSO4</intervention_name>
    <arm_group_label>St-Mg + P</arm_group_label>
    <arm_group_label>Std-Mg + Bud</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nebulized normal saline</intervention_name>
    <arm_group_label>Hi-Mg + P</arm_group_label>
    <arm_group_label>St-Mg + P</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Children 2-14 years of age.

          2. Known to have bronchial asthma.

          3. Presenting in severe asthma exacerbation

          4. Asthma severity score 8 or higher according to PRAM asthma severity .

        Exclusion Criteria:

          1. Prematurity &lt;34 weeks of gestation.

          2. Critically ill children requiring immediate intubation or ICU admission.

          3. Transfers from other institutions.

          4. Adverse drug reaction or allergy to budesonide,salbutamol,ipratropium bromide,
             prednisone, prednisolone, methylprednisolone, or magnesium sulfate.

          5. History of neuromuscular disease, cardiac disease, renal disease, liver disease.

          6. Underlying chronic lung disease.

          7. Radiographic evidence of pneumonia or lung collapse .

          8. Hemodynamic instability.

          9. Instrumented airway or Tracheotomy.

         10. Colostomy or ileostomy.

         11. Malabsorption disorder.

         12. Known vitamin D deficiency.

         13. Receiving Milk of Magnesium for Constipation

         14. Chronic diarrhea (duration for 2 weeks)

         15. Diuretics use.

         16. Immunodeficiency.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>14 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Khalid Alansari, MD</last_name>
    <role>Study Director</role>
    <affiliation>Sidra Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Khalid Alansari, MD</last_name>
    <phone>+974-55336166</phone>
    <email>kalansari@hamad.qa</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Faten Abumusa, MD</last_name>
    <phone>+974-55312922</phone>
    <email>fmoussa@hamad.qa</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hamad Medical Corporation</name>
      <address>
        <city>Doha</city>
        <zip>3050</zip>
        <country>Qatar</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Qatar</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>May 25, 2015</study_first_submitted>
  <study_first_submitted_qc>May 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 28, 2015</study_first_posted>
  <last_update_submitted>January 16, 2020</last_update_submitted>
  <last_update_submitted_qc>January 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bronchial Asthma</keyword>
  <keyword>Intravenous magnesium sulfate</keyword>
  <keyword>Inhaled budesonide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
    <mesh_term>Emergencies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Budesonide</mesh_term>
    <mesh_term>Magnesium Sulfate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

